Dydrogesterone in Early Pregnancy Before Fetal Heart Detection
Dydrogesterone should not be routinely started in early pregnancy before fetal heartbeat visualization, as the evidence does not support its use for preventing miscarriage in threatened miscarriage or improving pregnancy outcomes, and recent safety concerns regarding birth defects warrant caution.
Evidence Against Routine Use
The most recent high-quality randomized controlled trial demonstrates no benefit of dydrogesterone for preventing miscarriage:
A 2024 double-blind, placebo-controlled RCT found no significant difference in continuing pregnancy beyond 20 weeks between dydrogesterone (90.0%) and placebo (86.0%) groups (p = 0.538) in women with threatened miscarriage. 1
The trial used dydrogesterone 20 mg per day (10 mg twice daily) until one week after bleeding stopped or for a maximum of six weeks, starting at 6 to less than 20 weeks gestation. 1
Safety Concerns
Recent pharmacovigilance data raises significant safety concerns that must be considered:
A 2025 disproportionality analysis of the WHO global safety database (VigiBase) showed significantly increased reporting of birth defects with dydrogesterone exposure, particularly hypospadias and congenital heart defects. 2
The reporting odds ratio for birth defects with dydrogesterone was 5.4 (95% CI 3.7-7.9) when compared to progesterone, and 6.0 (95% CI 4.2-8.5) when compared to any other ART drug. 2
Major birth defects reported included genital defects (hypospadias) and congenital heart defects. 2
Limited Supporting Evidence
While older studies suggested potential benefit, they are outweighed by recent evidence:
A 2005 open-label study showed higher continuing pregnancy rates with dydrogesterone (95.9%) versus conservative treatment (86.3%, p=0.037) in threatened abortion, but this was not a blinded trial and predates current safety concerns. 3
A 2005 study protocol proposed investigating immunomodulation effects, but this represents theoretical rationale rather than proven clinical benefit. 4
Clinical Implications
Given the lack of demonstrated efficacy in the most recent high-quality trial and emerging safety signals regarding birth defects, dydrogesterone should not be initiated before fetal heart detection for miscarriage prevention. 1, 2
If Dydrogesterone Use is Considered Despite These Concerns:
The dosing regimen studied was 20 mg per day (10 mg twice daily) starting after presentation with threatened miscarriage. 1
Treatment duration was until one week after vaginal bleeding stopped or maximum six weeks. 1
Real-world data shows prescriptions ranging from 20-30 mg daily, with once-daily sustained-release formulations being increasingly used. 5
Important Caveats
The FDA drug label information provided in the evidence 6 pertains to estradiol transdermal systems for postmenopausal symptoms, not dydrogesterone in pregnancy, and should be disregarded for this clinical question.
The guideline evidence provided 7 addresses 17-hydroxyprogesterone caproate (17OHP-C) for prevention of preterm birth in women with prior spontaneous preterm birth, which is a different clinical scenario than early pregnancy threatened miscarriage before fetal heart detection.